Drug interactions
Nivolumab + Thalidomide
Severity: Major
Nivolumab and Thalidomide: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Thalidomide is an immunomodulator, and concurrent use with PD-1 antibodies in multiple myeloma has been linked to excess mortality in trials of pembrolizumab combinations. Nivolumab is expected to share this class risk, though direct evidence is limited. Outside a clinical trial the combination offers no proven benefit.
What this interaction means in plain words
Nivolumab and Thalidomide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Nivolumab belongs to Oncology; Thalidomide belongs to Miscellaneous.
Why it happens
Combined immune modulation with PD-1 blockade and thalidomide analogs; the mechanism of excess harm is not fully established.
What to do
Avoid combining nivolumab with thalidomide or related agents in multiple myeloma outside a clinical trial. If used, monitor closely for immune-related adverse events and infections.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Nivolumab and Thalidomide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Nivolumab
- Dexamethasone-tobramycin + Nivolumab Moderate
- Dexamethasone + Nivolumab Moderate
- Efgartigimod / hyaluronidase sc + Nivolumab Moderate
- Efgartigimod alfa + Nivolumab Moderate
- Nivolumab + Ponesimod Moderate
- Nivolumab + Rozanolixizumab Moderate
Other interactions of Thalidomide
Frequently asked questions
Can I take Nivolumab with Thalidomide?
MediHelp rates the interaction as major. Nivolumab and Thalidomide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Thalidomide is an immunomodulator, and concurrent use with PD-1 antibodies in multiple myeloma has been linked to excess mortality in trials of pembrolizumab combinations. Nivolumab is expected to share this class risk, though direct evidence is limited. Outside a clinical trial the combination offers no proven benefit.
How serious is the interaction between Nivolumab and Thalidomide?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining nivolumab with thalidomide or related agents in multiple myeloma outside a clinical trial. If used, monitor closely for immune-related adverse events and infections.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Dexamethasone-tobramycin, Dexamethasone, Efgartigimod / hyaluronidase sc. The full list is on the Nivolumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
